[HTML][HTML] Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations
K Yau, A Dharia, I Alrowiyti, DZI Cherney - Kidney international reports, 2022 - Elsevier
SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
Progress in the treatment of diabetic cardiomyopathy, a systematic review
Y Shou, X Li, Q Fang, A Xie, Y Zhang… - Pharmacology …, 2024 - Wiley Online Library
Diabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that
occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease …
occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease …
Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and …
The disease burden of heart failure (HF) is approximately 1–2% worldwide, and the clinical
course of HF leaves patients with a poor quality of life. In addition, HF remains a common …
course of HF leaves patients with a poor quality of life. In addition, HF remains a common …
Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study
A Alsalem, MM Alsultan, F Alqarni… - Frontiers in …, 2024 - frontiersin.org
Background: Heart failure (HF) was estimated to impact approximately 64 million individuals
worldwide in 2017 and is predicted to rise in the coming years. Therefore, the aim of our …
worldwide in 2017 and is predicted to rise in the coming years. Therefore, the aim of our …
Sodium–Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction
M Asakura-Kinoshita, T Masuda, K Oka, K Ohara… - Diagnostics, 2024 - mdpi.com
We previously reported that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert
sustained fluid homeostatic actions through compensatory increases in osmotic diuresis …
sustained fluid homeostatic actions through compensatory increases in osmotic diuresis …
Changes in diuretic medication prescribing and surrogate laboratory parameters after initiating empagliflozin in veterans (CHAMPION Cohort Study)
T Patil, E Halsey, A Kaur, J Minchak, J Hobson… - Clinical Drug …, 2023 - Springer
Abstract Background and Objectives Sodium-glucose cotransporter type 2 inhibitors have
evolved into a novel drug class utilized for reductions in cardiovascular risk and heart failure …
evolved into a novel drug class utilized for reductions in cardiovascular risk and heart failure …
Impact of dapagliflozin on the renal function and damage in patients with heart failure with a reduced ejection fraction
M Nakase, K Ninomiya, Y Horiuchi, M Sekiguchi… - Internal …, 2024 - jstage.jst.go.jp
Objective Whether or not the initial dip in the glomerular filtration rate (GFR) after the
initiation of sodium-glucose co-transporter 2 inhibitors (SGLT2is) is associated with renal …
initiation of sodium-glucose co-transporter 2 inhibitors (SGLT2is) is associated with renal …